Lineage Cell Therapeutics Inc. (AMEX: LCTX) stock jumped 8.59% on Friday to $1.77 against a previous-day closing price of $1.63. With 1.02 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.91 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.7900 whereas the lowest price it dropped to was $1.6300. The 52-week range on LCTX shows that it touched its highest point at $2.80 and its lowest point at $1.10 during that stretch. It currently has a 1-year price target of $6.00. Beta for the stock currently stands at 1.58.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LCTX was up-trending over the past week, with a rise of 9.26%, but this was up by 5.99% over a month. Three-month performance surged to 36.15% while six-month performance rose 17.22%. The stock lost -30.86% in the past year, while it has lost -27.76% so far this year. A look at the trailing 12-month EPS for LCTX yields -0.29 with Next year EPS estimates of 0.17. For the next quarter, that number is -0.04. This implies an EPS growth rate of -90.00% for this year and 300.00% for next year.
Float and Shares Shorts:
At present, 169.65 million LCTX shares are outstanding with a float of 161.81 million shares on hand for trading. On Jul 14, 2022, short shares totaled 4.97 million, which was 2.93% higher than short shares on Jun 14, 2022. In addition to Mr. Brian M. Culley M.A., M.B.A. as the firm’s CEO, Pres, Interim CFO, Principal Financial Officer & Director, Mr. George A. Samuel III, J.D. serves as its Gen. Counsel & Company Sec.
Through their ownership of 43.12% of LCTX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 38.26% of LCTX, in contrast to 25.20% held by mutual funds. Shares owned by individuals account for 10.12%. As the largest shareholder in LCTX with 20.58% of the stake, Broadwood Capital, Inc. holds 34,935,485 shares worth 34,935,485. A second-largest stockholder of LCTX, BlackRock Fund Advisors, holds 9,146,940 shares, controlling over 5.39% of the firm’s shares. Greenway Partners LP is the third largest shareholder in LCTX, holding 6,874,242 shares or 4.05% stake. With a 2.34% stake in LCTX, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 3,973,146 shares are owned by the mutual fund manager. The British & American Investment Tru, which owns about 1.34% of LCTX stock, is the second-largest Mutual Fund holder. It holds 2,271,053 shares valued at 3.59 million. Vanguard Extended Market Index Fu holds 1.00% of the stake in LCTX, owning 1,704,495 shares worth 2.69 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LCTX since 7 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With LCTX analysts setting a high price target of $8.00 and a low target of $4.00, the average target price over the next 12 months is $6.00. Based on these targets, LCTX could surge 351.98% to reach the target high and rise by 125.99% to reach the target low. Reaching the average price target will result in a growth of 238.98% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. LCTX will report FY 2022 earnings on 03/16/2023. Analysts have provided yearly estimates in a range of -$0.10 being high and -$0.22 being low. For LCTX, this leads to a yearly average estimate of -$0.15. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Lineage Cell Therapeutics Inc. surprised analysts by -$0.02 when it reported -$0.04 EPS against a consensus estimate of -$0.02. The surprise factor in the prior quarter was -$0.12. Based on analyst estimates, the high estimate for the next quarter is -$0.01 and the low estimate is -$0.06. The average estimate for the next quarter is thus -$0.03.
Summary of Insider Activity:
Insiders traded LCTX stock several times over the past three months with 1 Buys and 1 Sells. In these transactions, 15,450 shares were bought while 5,343 shares were sold. The number of buy transactions has increased to 18 while that of sell transactions has risen to 8 over the past year. The total number of shares bought during that period was 1,556,394 while 575,355 shares were sold.